Back to Directory Kathy Kosch Email kathy.kosch@abbvie.com Institution AbbVie Title Senior Scientific Director, HCV Request an Update Affiliated Studies IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in People with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status In Development
IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in People with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status In Development
